Overview of Prolertus

Property	Description
Active Ingredient	Diclofenac (as Diclofenac Colestiramina)
Form	Hard Gelatin Capsule
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose	Relief of Pain and Inflammation
Origin	Synthetic

What Type of Medicine is Prolertus and its Origin?

Prolertus is a synthetic, prescription-only medication classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its identity is defined by the active ingredient Diclofenac, a compound derived from phenylacetic acid. This medication belongs unequivocally to the NSAID pharmacological class, distinguishing it as a potent analgesic and anti-inflammatory agent. Diclofenac's efficacy is clinically recognized for its role in reducing discomfort associated with general inflammatory conditions. Diclofenac is one of the most widely used non-steroidal anti-inflammatory medicines globally. This confirms the medication is an established and primary tool for managing general inflammation and pain.

Composition and Prolonged-Release Formulation

The active component in Prolertus is the unique salt formulation, Diclofenac Colestiramina (Diclofenac Cholestyramine). This single-ingredient product is administered orally in the form of a hard gelatin capsule. This formulation is engineered as a prolonged-release system, which structurally differs from immediate-release Diclofenac products by utilizing a carrier resin (cholestyramine) to control the rate at which the active substance is made systemically available. The controlled-release design aims to maintain consistent plasma concentrations over time, reducing the need for frequent dosing. This sustained delivery system is a key differentiating factor, intended to provide steady relief without sharp fluctuations in effect, supporting conditions that require continuous pain modulation.

General Purpose: Relief of Pain and Inflammation

The general purpose of Prolertus is to provide systemic relief by acting directly on the processes that cause discomfort. Like all NSAIDs, Diclofenac works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins, which are the chemical messengers responsible for triggering pain and inflammation. By controlling the generation of these key inflammatory signals, the medication effectively addresses the swelling, tenderness, and aching linked to the body's inflammatory response. For example, Prolertus would typically be used to manage acute discomfort following certain medical procedures or general musculo-skeletal strain. The sustained delivery from the prolonged-release capsule is a unique attribute aimed at supporting consistent therapeutic action over time.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Prolertus?

Possible side effects and safety information

Official Adverse Reaction Profile

The safety profile of Prolertus (Diclofenac) is defined by its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID). Adverse reactions are formally grouped by System-Organ Class (SOC) and assigned an official frequency (e.g., Very Common, Common, Rare) based on regulatory standards.

Effects classified as Common often relate to the Gastrointestinal System, including nausea, vomiting, dyspepsia, abdominal pain, flatulence, and diarrhea. Nervous System effects such as headache and dizziness are also commonly reported. Official documentation requires monitoring for Hepatic effects, as elevations in liver transaminases are common.

Serious Safety Considerations

The most serious documented risks are inherent to the NSAID class, and official labels carry prominent warnings for these events. These include potentially fatal Cardiovascular Thrombotic Events such as myocardial infarction and stroke, with the risk potentially increasing with the duration of use and occurring early in treatment.

Serious Gastrointestinal Adverse Events, including ulceration, bleeding, and perforation of the stomach or intestines, can occur at any time without warning symptoms. Additionally, rare but severe Dermatological Reactions (such as Stevens-Johnson Syndrome) and Hepatotoxicity (including liver failure) are documented in regulatory sources.

Population-Specific Constraints

The medicine is contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of aspirin-sensitive asthma. It is also absolutely contraindicated during the third trimester of pregnancy due to the risk of fetal cardiopulmonary toxicity. Older adults are officially noted to be at a greater risk for serious gastrointestinal adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Prolertus (Diclofenac Colestiramina) overdose outlines documented manifestations and mandated emergency actions. Severe outcomes, including acute renal failure, hepatic damage/dysfunction, and gastrointestinal haemorrhage, are associated with the ingestion of large quantities.

Non-specific clinical manifestations documented in official labeling may include epigastric pain, nausea, vomiting, headache, tinnitus, and drowsiness. In the most severe cases of poisoning, central nervous system effects such as seizures or coma have been reported.

Mandatory Emergency Action:

Seek immediate medical attention or contact emergency services is explicitly required for any suspected large over-ingestion. Following this action, hospital monitoring of vital signs, and of renal and hepatic function, is typically required to manage potential organ toxicity.

Management and Risk:

Management is limited to symptomatic and supportive treatment, as no specific antidote is known to be available for Diclofenac toxicity. Official documents note that the risk of severe outcomes is higher in individuals with pre-existing renal or hepatic impairment. Procedural steps such as gastric lavage or administration of activated charcoal may be considered, depending on the time elapsed since ingestion.

This structured profile defines the necessary urgent response and the scope of complications recognized by regulatory authorities.

Therapeutic Uses of Prolertus

What Prolertus Treats: Main Uses and Benefits

The core therapeutic purpose of Prolertus (Diclofenac Colestiramina) is relevant for easing symptoms related to inflammatory or irritative states. The medication is commonly used to help with symptoms related to physical discomfort and systemic imbalance across a wide range of conditions.

It is commonly used across conditions involving inflammatory processes, such as chronic disorders like Rheumatoid Arthritis and Osteoarthritis, to help with symptom clusters that include pain, localized swelling, and stiffness. It is applied in addressing symptoms related to physical discomfort following sudden events like trauma (sprains), post-operative discomfort after surgical/dental procedures, and severe episodic manifestations such as Renal Colic or primary Dysmenorrhea.

In these scenarios, Prolertus contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability, offering symptomatic relief during phases when symptoms become temporarily overwhelming.

Quick Fact: Used for managing Inflammation and Pain

Eligibility and Restrictions for Use

The eligibility for Prolertus (Diclofenac Colestiramina) is defined by official regulatory criteria, primarily establishing who is absolutely prohibited from using the medicine. Use is generally established for adults who do not possess any of the documented contraindications.

Population Eligibility Status	Official Regulatory Stance
Contraindicated Groups	Patients with known hypersensitivity to Diclofenac or other NSAIDs, severe organ failure (heart, liver, or kidney), active gastrointestinal ulceration/bleeding, and women in the third trimester of pregnancy. Use is also prohibited after coronary artery bypass graft (CABG) surgery.
Restricted or Conditional Use	Use requires special caution and monitoring in older adults, and in patients with a prior history of GI disease, mild to moderate organ impairment (hepatic or renal), or uncontrolled hypertension.

Age and Developmental Status: Use is generally not recommended or not established for children and adolescents under 18 years of age, as safety data are often insufficient for this formulation. For women, Prolertus is contraindicated during the third trimester of pregnancy and not recommended while breastfeeding. Regulatory documents strictly classify usage into these groups, with absolute prohibitions applying to specific populations where the risks are deemed unacceptable.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines the officially documented interaction profile of Prolertus (Diclofenac Colestiramina) as defined in government regulatory labeling.

Classification	Interacting Product Category	Official Statement on Interaction
Contraindicated	Other Systemic NSAIDs	Prohibited due to significantly increased risk of serious gastrointestinal adverse events.
Contraindicated	Aspirin (Analgesic doses)	May diminish the antiplatelet effect and is prohibited in aspirin-sensitive asthma.
Exposure Increase	Lithium and Methotrexate	Co-administration increases the serum concentration of the co-administered drug due to reduced renal clearance.
Pharmacokinetic	Strong CYP2C9 Inhibitors (e.g., Voriconazole)	PK interaction resulting in a documented increase in Diclofenac plasma exposure.
Pharmacodynamic	Anticoagulants/SSRIs/Corticosteroids	Increases the documented risk of serious gastrointestinal bleeding.
Pharmacodynamic	ACE Inhibitors/ARBs/Diuretics	May diminish antihypertensive/diuretic effects and increase the risk of deterioration of renal function.

Timing-Based Administration Rule: Due to the Cholestyramine carrier resin component, which acts as a non-specific binder, other concurrently administered oral medications may require timing separation (e.g., 1 hour before or 4-6 hours after) to prevent reduced systemic exposure of the co-administered drug. The label also states that consumption of alcohol increases the risk of serious gastrointestinal bleeding. A population note specifies an increased risk of renal function deterioration when co-administered with ARBs or ACE inhibitors in elderly, volume-depleted, or renally impaired patients.

The regulatory documents define this product's interaction structure by establishing formal prohibitions for co-administration with other systemic NSAIDs, alongside defining high-risk pharmacokinetic changes that alter the drug concentrations of co-administered agents like Lithium. This is further constrained by the physical properties of the Cholestyramine carrier resin, which necessitates specific timing rules for administering other oral medications to prevent a reduction in their systemic exposure.

Mechanism of Action

Molecular Blockade of Cyclooxygenase (COX) Enzymes

The drug's primary action is the non-selective inhibition of the COX-1 and COX-2 enzymes. This enzymatic blockade interrupts the body’s Arachidonic Acid Cascade, which is the fundamental process responsible for synthesizing prostaglandins. This suppression of mediator production is the molecular foundation for all subsequent physiological effects.

Modulation of Peripheral Nociceptive Signaling

By reducing the synthesis of inflammatory prostaglandins, the drug directly affects the nociceptive signaling pathway by minimizing the chemical sensitization of peripheral nerve endings. This reduced sensitivity physiologically results in a reduced excitation of peripheral nociceceptors, which lessens the transmission of peripheral sensory input to the central nervous system.

Modulation of Localized Vascular and Systemic Thermoregulatory Pathways

The mechanism affects two systemic physiological processes: localized vascular response and central thermoregulation. Peripherally, the reduction in prostaglandins curtails local vasodilation and capillary permeability, leading to a moderation of localized tissue reactivity and reducing fluid extravasation into the interstitial space; centrally, the suppression of prostaglandin E2 synthesis in the hypothalamus allows for the physiological resetting of the central thermoregulatory set point.

Dosage and Administration Information

Official Instructions for Use

Prolertus (Diclofenac Colestiramina) is administered orally using its specialized prolonged-release hard gelatin capsule formulation. This delivery mechanism is designed to sustain the release of the active ingredient over time, which dictates the strict administration protocol.

Standard Dosing Principles

The usual daily dose for oral, prolonged-release Diclofenac typically ranges from 75 mg to 150 mg (Diclofenac equivalent). A strict maximum limit of 150 mg is the highest recommended daily dose for oral administration. The medication is used at the lowest effective dose for the shortest duration necessary. The prolonged-release form is typically administered once daily.

Administration Requirements

To preserve the controlled-release mechanism, the capsule must be swallowed whole with an adequate amount of liquid and must not be crushed, broken, or chewed. This procedural step is essential for proper systemic absorption. The medication may be taken with or after food to minimize potential gastrointestinal discomfort.

Population-Specific Guidance

For older adults, the prescribing information advises utilizing the lowest effective dosage. Furthermore, this prolonged-release formulation is not suitable for use in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of studies for Prolertus

Evidence for use in Chronic Inflammatory Arthritis

This section will summarize the structure of clinical evaluation exploring how symptoms change over time in conditions such as Osteoarthritis and Rheumatoid Arthritis. It will describe the use of Randomized Controlled Trials (RCTs) and Systematic Reviews to measure outcomes related to physical discomfort and daily functioning.

Research examined adult patients diagnosed with symptomatic Osteoarthritis (OA) or Rheumatoid Arthritis (RA). The evidence base for this compound class relies on Randomized Controlled Trials (RCTs), which compare different formulations of Diclofenac against standard treatments and control groups. Researchers utilized objective measures of Pain intensity and standardized functional scores to gauge perceived discomfort.

Findings describe patterns observed in the studies related to Pain intensity and Physical function during the research period. Studies explored how symptoms evolved in the observed populations with conditions marked by functional limitations. Reported outcomes were measured over defined time intervals, with the research providing context but not individual predictions about symptom changes.

Long-term effects are not fully established because follow-up durations were limited in many initial efficacy trials. Existing studies provide limited insight into sustained symptomatic stability over periods exceeding a few months. Research is ongoing to better understand symptom patterns over extended use, and data for certain groups of patients with complex health issues remain insufficient.

Evidence for use in Acute Pain and Inflammatory States

This part of the section will outline the research base for managing transient, acute pain following events like trauma, surgery, or low back pain. The summary will focus on evidence from both controlled studies and large-scale observational research that examined outcomes related to episodic or acute changes.

For conditions associated with acute or disruptive episodes, such as short-term low back pain or discomfort following procedures, research examined patient-reported outcomes describing perceived discomfort. The evidence base includes controlled clinical studies and large-scale observational research (post-marketing surveillance) involving large cohorts of adult patients. Studies observed responses over defined time intervals to capture outcomes describing episodic or acute changes.

Findings describe patterns observed in the studies related to Pain score and overall Global Efficacy Assessments within very short follow-up durations. Research provides insight into short-term changes and documented patterns related to the perceived time to onset and duration of the medicine’s action, reflecting research conducted during periods of increased symptom activity.

The evidence for acute pain is inherently very short-term, generally reflecting follow-up durations that were limited to 10 days or less. Therefore, research does not include long-term outcomes or the durability of effect. Additionally, the data derived from large observational settings may rely heavily on physician and patient self-reported assessments, meaning evidence quality varies across studies.

Long-Term Studies and Durability of Response

This crucial section will summarize the available evidence on extended follow-up and maintenance of effect for Prolertus and its compound class, particularly in chronic conditions like Ankylosing Spondylitis. It will clarify the type of data, such as assessments of structural changes, that exist for longer durations.

For chronic inflammatory diseases affecting the spine, such as Ankylosing Spondylitis (AS), studies explored long-term structural outcomes. Research examined temporary physiological imbalance alongside assessments of Radiographic progression and changes in structural integrity over extended periods. These long-term clinical trials involved monitoring patients for up to two years to evaluate changes in disease activity and physical function.

Research describes documented measurements of Radiographic outcomes during the follow-up periods. Data show patterns related to structural changes that were observed in some studies. However, evidence suggests that findings were mixed across different study cohorts, with reports of structural change measurements varying.

Certainty remains low regarding the data for long-term outcomes, particularly concerning structural changes, and findings were mixed across trials. Follow-up durations were limited for many types of studies, and the results apply only to the populations studied within these long-term AS trials. Therefore, certainty remains low when extrapolating this data to other chronic conditions or patient groups.

Evidence in Specific Patient Groups

This section will outline what is known about the research conducted in specific patient populations and age groups, such as the data collected on older adults or patients with specific disease profiles. It will describe the focus of the research as it relates to these distinct groups, when available in the regulatory record.

Research examined how Diclofenac formulations were observed in adult patients of varying age ranges, particularly those with OA and RA. Studies explored patient-reported experiences for specific conditions involving periods of heightened symptoms, such as primary dysmenorrhea (menstrual pain).

Findings describe patterns observed in these population groups, with research contributing to the broader evidence landscape. However, evidence is limited when focusing on highly specific subgroups.

Data for certain groups, including children or the frail elderly with multiple chronic conditions, remain insufficient. There is limited information for long-term outcomes in groups defined by certain comorbidities, meaning results apply only to the populations studied in the main RCTs.

Research Gaps and Areas of Uncertainty

This final section will synthesize the main limitations identified within the published research, including common study issues like short trial durations for chronic conditions, variability in reported outcomes across different trials, and specific evidence gaps that remain unaddressed in the scientific literature.

Research highlights what is known and what is still uncertain about the use of Prolertus. For the treatment of chronic conditions, follow-up durations were limited in many primary efficacy studies, often focusing only on short-term symptom relief. This means long-term effects are not fully established regarding sustained symptom control.

Additionally, comparative evidence specific to the prolonged-release formulation and its long-term impact compared to other continuous-release NSAIDs is limited. Subgroup findings are uncertain, as sample sizes were modest for examining patients with specific, complex health issues. Evidence quality varies across studies, and data for certain groups remains insufficient. Research is ongoing to address these open questions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Prolertus (FAQ)

Q: Is Prolertus a controlled substance according to drug regulatory schedules?

Prolertus contains Diclofenac, which belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. According to regulatory scheduling, this medication is generally not classified as a controlled substance. This means it is not associated with the same risks of dependence that controlled substances carry.

Q: Are the common side effects of Prolertus usually mild or severe?

Official product safety information groups adverse effects by how often they occur. Effects listed as common, such as dizziness, nausea, and headache, are typically reported and monitored separately from the more serious, though rare, safety events. The serious safety considerations include risks like heart attack, stroke, or severe gastrointestinal bleeding.

Q: Does Prolertus have any known effects on appetite or body weight?

Studies and official product information indicate that changes in appetite or unexplained weight gain are included in the list of possible effects. These are not considered common reactions. The official label suggests that these effects should be communicated to the healthcare provider.

Q: Is it true that Prolertus can cause changes to sleep patterns?

According to the official product information, effects on the nervous system are possible. These may include dizziness or feeling sleepy. The official information notes that these effects have the potential to impact activities that require concentration, such as driving.

Q: Does Prolertus interact with common dietary supplements like Vitamin D or St. John's Wort?

Official regulatory guidance specifically warns against combining Prolertus with certain drug classes that could increase the risk of internal bleeding. Many herbal products, like St. John’s Wort, may require caution or timing separation because of their potential to interfere with how other medications are processed by the body.

Q: What are the general expectations if a dose of Prolertus is missed?

Regulatory instructions outline a protocol for missed doses. This protocol indicates that extra medication must not be taken to compensate for a missed dose and requires adhering to the scheduled administration times.

Q: Has Prolertus been involved in any recent regulatory safety updates or alerts?

The drug class to which Prolertus belongs (Diclofenac) is subject to continuous regulatory monitoring, known as pharmacovigilance. Due to this ongoing safety review, particularly concerning cardiovascular risks, some regulatory bodies have reinforced prescribing precautions and restricted its availability to prescription-only status.

Q: Is Prolertus available in a generic formulation?

Generic versions of the active ingredient, Diclofenac, are widely available in several forms. However, the specific availability of the generic form of the unique Diclofenac Colestiramina prolonged-release capsule depends on its individual patent and market approval status in a given country.

Q: Does Prolertus carry a risk of physical dependence or withdrawal symptoms?

According to regulatory classification, Prolertus is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not a controlled substance. For this reason, official safety information indicates that the medication does not carry a documented risk of physical dependence or a recognized withdrawal syndrome upon discontinuation.

Q: What type of healthcare professional is typically authorized to prescribe Prolertus?

Prolertus is classified as a prescription-only medicine (POM) in most regions. This classification is due to the potential for serious cardiovascular and gastrointestinal risks, which necessitates the diagnosis, judgment, and oversight of a licensed healthcare professional for its safe use.

Q: What is the difference between an 'adverse reaction' and a 'side effect' for Prolertus?

Although these terms are often used interchangeably, official pharmacovigilance reports may distinguish between them. An adverse reaction typically refers to an unexpected, harmful response that occurs at normal doses. A side effect is a broader term for any predictable, unintended outcome of the medicine.

Q: What are the official guidelines regarding stopping Prolertus treatment?

Official guidance confirms that the decision to stop or alter medication is determined by the prescribing doctor's assessment. In cases of acute concerns, regulatory advice outlines that a patient may temporarily discontinue the medicine while seeking immediate medical consultation.

How should Prolertus be stored and disposed of?

How to Store and Dispose of Prolertus?

The storage and handling of Prolertus (Diclofenac Colestiramina) must adhere strictly to regulatory conditions to maintain the stability of the hard gelatin capsules.

Official Storage Conditions

Storage Requirement	Specification
Temperature	Do not store above 25 C.
Protection	Protect from both light and moisture.
Container	Keep in the original container or packaging.
Child Safety	Keep out of the sight and reach of children.

Disposal Requirements

Official disposal instructions require that unused or expired Prolertus must be discarded according to local regulatory requirements. It must not be disposed of via wastewater or thrown into regular household waste. Consulting a pharmacist or using a medicine take-back program is the advised method for proper disposal.

Prolertus